SELDI蛋白质指纹对因基因多态性导致耐药性漂移诊断的前瞻性研究——吉非替尼与含铂方案序贯治疗非小细胞肺癌

BACKGROUND AND OBJECTIVE: This study aims to observe the long-term effects of sequential therapy with a platinum-based regimen and gefitinib for non-small cell lung carcinoma (NSCLC) with failed chemotherapy under the guidance of surface-enhanced laser desorption/ionization (SELDI). METHODS: Nine NSCLC patients with failed chemotherapy and ≤15% abundance of M/Z: 8, 693±50H(+) were selected. The patients were administered with 250 mg of gefitinib (p.o., once a day). During the therapy, SELDI was applied every 2 months. If the M/Z: 8, 693±50H(+) abundance was > 25%, chemotherapy was applied; if the abundance was ≤15%, gefitinib (p.o.) was applied. In between, we chose gefitinib according to the mass and tumor markers. On the base, we sequentially applied the drug and observed the total survival time. RESULTS: Follow-ups until December 2010 revealed that the median overall survival time of the nine patients was 27 months (10 months-66 months). CONCLUSION: The treatment benefit ratio and benefit time of anti-NSCLC drugs can be improved by SELDI fingerprinting.